• Explore /
  • Poster
  • / Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010).

Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010).

Abstract Poster

Authors

null

Alistair E. Ring

The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom

Alistair E. Ring , Laura Moretti , Angelica Afshari-Mehr , Andrew M. Wardley , Lucy Kilburn , Bora Gurel , Iain R. MacPherson , Richard D. Baird , Sue Martin , Alex Pearson , Rebecca Roylance , Matthew Winter , Kathryn Dunne , Ellen Copson , Tamas Hickish , Peter Stephens , Russell J. Burcombe , Katrina Randle , Judith Bliss , Nicholas C. Turner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

ISRCTN16945804

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 1024)

DOI

10.1200/JCO.2022.40.16_suppl.1024

Abstract #

1024

Poster Bd #

402

Abstract Disclosures

Similar Posters

First Author: Juan De La Haba

First Author: James O'Bryan

First Author: Natalia Lukashchuk

First Author: Zachery R Reichert